MX2017000628A - Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. - Google Patents

Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.

Info

Publication number
MX2017000628A
MX2017000628A MX2017000628A MX2017000628A MX2017000628A MX 2017000628 A MX2017000628 A MX 2017000628A MX 2017000628 A MX2017000628 A MX 2017000628A MX 2017000628 A MX2017000628 A MX 2017000628A MX 2017000628 A MX2017000628 A MX 2017000628A
Authority
MX
Mexico
Prior art keywords
methods
hypercholesterolemia
cardiovascular risk
high cardiovascular
present
Prior art date
Application number
MX2017000628A
Other languages
English (en)
Other versions
MX378872B (es
Inventor
Bessac Laurence
Chaudhari Umesh
Hanotin Corinne
A Schwemmer Gipe Daniel
Pordy Robert
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2017000628A publication Critical patent/MX2017000628A/es
Publication of MX378872B publication Critical patent/MX378872B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para tratar la hipercolesterolemia. Los métodos de la presente invención comprenden administrar a un paciente de alto riesgo cardiovascular una composición farmacéutica que comprende un inhibidor de PCSK9. En determinadas modalidades, el inhibidor de PCSK9 es un anticuerpo anti-PCSK9, tal como el anticuerpo ilustrativo referido en la presente descripción como mAb316P. Los métodos de la presente invención son útiles para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia y cardiopatía coronaria (CC) establecida o equivalentes de riesgo de CC no adecuadamente controladas con terapia de estatinas a la dosis máxima tolerada. dosis máxima tolerada.
MX2017000628A 2014-07-16 2015-07-16 Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. MX378872B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462025371P 2014-07-16 2014-07-16
US201462043167P 2014-08-28 2014-08-28
US201462080725P 2014-11-17 2014-11-17
US201562132709P 2015-03-13 2015-03-13
EP15305830 2015-05-29
PCT/US2015/040765 WO2016011260A1 (en) 2014-07-16 2015-07-16 Methods for treating high cardiovascular risk patients with hypercholesterolemia

Publications (2)

Publication Number Publication Date
MX2017000628A true MX2017000628A (es) 2017-04-27
MX378872B MX378872B (es) 2025-03-11

Family

ID=53365943

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017000628A MX378872B (es) 2014-07-16 2015-07-16 Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2021000289A MX2021000289A (es) 2014-07-16 2017-01-13 Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000289A MX2021000289A (es) 2014-07-16 2017-01-13 Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.

Country Status (12)

Country Link
US (2) US20160137746A1 (es)
EP (2) EP3169362B1 (es)
JP (1) JP6912374B2 (es)
KR (3) KR20230007538A (es)
CN (2) CN107106678A (es)
AU (1) AU2015289617B2 (es)
CA (1) CA2955304C (es)
MX (2) MX378872B (es)
PL (1) PL3169362T3 (es)
RU (1) RU2723018C2 (es)
WO (1) WO2016011260A1 (es)
ZA (1) ZA201700196B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
EP3197492A1 (en) * 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
TW201904608A (zh) * 2017-06-09 2019-02-01 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
IL277127B2 (en) * 2018-03-06 2025-11-01 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
JP2023501745A (ja) * 2019-11-18 2023-01-18 エーディー ファーマシューティカルズ カンパニー，リミティド 抗ｐｃｓｋ９抗体及びその使用
MX2023001481A (es) * 2020-08-07 2023-03-08 Regeneron Pharma Metodos para tratar pacientes con hipercolesterolemia refractaria.
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途
CN117586402A (zh) * 2023-10-20 2024-02-23 合肥天港免疫药物有限公司 NKp80抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2825778A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
ES2773111T3 (es) * 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
CN114558129A (zh) * 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法

Also Published As

Publication number Publication date
PL3169362T3 (pl) 2020-12-28
MX2021000289A (es) 2021-03-31
JP6912374B2 (ja) 2021-08-04
KR20170028441A (ko) 2017-03-13
AU2015289617B2 (en) 2021-04-15
RU2723018C2 (ru) 2020-06-08
RU2017104799A (ru) 2018-08-16
WO2016011260A1 (en) 2016-01-21
CN107106678A (zh) 2017-08-29
EP3169362A1 (en) 2017-05-24
EP3753575A1 (en) 2020-12-23
ZA201700196B (en) 2024-09-25
CN114306592A (zh) 2022-04-12
CA2955304C (en) 2023-12-12
US20160137746A1 (en) 2016-05-19
KR102482375B1 (ko) 2022-12-29
CA2955304A1 (en) 2016-01-21
US20200255544A1 (en) 2020-08-13
AU2015289617A1 (en) 2017-02-02
KR20230007538A (ko) 2023-01-12
EP3169362B1 (en) 2020-06-10
MX378872B (es) 2025-03-11
RU2017104799A3 (es) 2019-02-19
JP2017522316A (ja) 2017-08-10
KR20240132123A (ko) 2024-09-02

Similar Documents

Publication Publication Date Title
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX378872B (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
MX2019003134A (es) Terapia de combinacion.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2017011499A (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX390751B (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina